Vir will engineer three masked T-cell engager candidates for Gilead. Gilead gets exclusive rights to develop and commercialise them, in return for USD 90 million upfront and potential milestone payments.
Alaunos has completed its acquisition of Velaris, adding a portfolio of cardiopulmonary biologics. Four other companies reported advances in Alzheimer’s AI and cancer research, alongside updates on protein production and predictive toxicology.
At one Chinese hospital, 13 of 14 patients whose B-cell acute lymphoblastic leukemia returned after a stem-cell transplant reportedly achieved complete remission. Seven of eight patients with disease outside the bone marrow also responded, but independent research does not verify the results.
Researchers are breaking down old barriers by enrolling patients with HIV-associated lymphoma in CAR T and bispecific antibody trials. This shift is forcing a rethink of who gets access to advanced cancer immunotherapies.
